Basaglar 100 Units/Ml Pfp 5 Pens Of 3 Ml (Refrigerator)

Product Description:

• BASAGLAR contains insulin glargine. This is a modified insulin, very similar to human insulin.
• BASAGLAR is used to treat diabetes mellitus in adults, adolescents and children aged 2 years and 
• Diabetes mellitus is a disease where your body does not produce enough insulin to control the level of 
• blood sugar. Insulin glargine has a long and steady blood sugar lowering action.

How to use:

• A new needle must be attached before each use. Only use needles that are compatible for use with
• BASAGLAR KwikPen.
• A safety test must be performed before each injection.
• Look at the cartridge before you use the pen. Do not use BASAGLAR KwikPen if you notice particles 
• in it. Only use BASAGLAR KwikPen if the solution is clear, colorless and waterlike. Do not shake 
• or mix it before use.
• To prevent the possible transmission of disease, each pen must be used by one patient only.
• Make sure that neither alcohol nor other disinfectants or other substances contaminate the insulin.
• BASAGLAR is injected under the skin. Do NOT inject BASAGLAR in a vein, since this will change 
• its action and may cause hypoglycemia.
• Your doctor will show you in which area of the skin you should inject BASAGLAR. With each 
• injection, change the puncture site within the particular area of skin that you are using.
• Basaglar is administered subcutaneously by injection in the abdominal wall, the thigh, the upper 
• arm, the deltoid region or the gluteal region. Injection sites should always be rotated within the 
• same region in order to reduce the risk of lipodystrophy and cutaneous amyloidosis.
• Always use a new pen if you notice that your blood sugar control is unexpectedly getting worse. If you 
• think you may have a problem with BASAGLAR KwikPen, consult your doctor, pharmacist or nurse.
• Empty pens must not be refilled and must be properly discarded.
• Do not use BASAGLAR KwikPen if it is damaged or not working properly, it has to be discarded and 
• a new KwikPen has to be used.

Caution & Warnings:

• Talk to your doctor, pharmacist or nurse before using BASAGLAR.
• Follow closely the instructions for posology, monitoring (blood and urine tests), diet and physical 
• activity (physical work and exercise) as discussed with your doctor.

Skin changes at the injection site.

• The injection site should be rotated to prevent skin changes such as lumps under the skin. The insulin 
• may not work well if you inject into a lumpy area (See How to use Basaglar). Contact your doctor if you are currently injecting into a lumpy area before you start injecting into a different area. Your 
• doctor may tell you to check your blood sugar more closely, and to adjust your insulin or your other 
• antidiabetic medications dose.

Travel

• Before travelling consult your doctor. You may need to talk about:
• the availability of your insulin in the country you are visiting,
• supplies of insulin etc.
• correct storage of your insulin while travelling,
• timing of meals and insulin administration while travelling,
• the possible effects of changing to different time zones,
• possible new health risks in the countries to be visited,
• what you should do in emergency situations when you feel unwell or become ill.

Illnesses and injuries

• In the following situations, the management of your diabetes may require a lot of care (for example, 
• adjustment to insulin dose, blood and urine tests):
• If you are ill or have a major injury then your blood sugar level may increase (hyperglycemia).
• If you are not eating enough your blood sugar level may become too low (hypoglycemia).
• In most cases you will need a doctor. Make sure that you contact a doctor early.
• If you have type 1 diabetes (insulin dependent diabetes mellitus), do not stop your insulin and continue 
• to get enough carbohydrates. Always tell people who are caring for you or treating you that you 
• require insulin.
• Insulin treatment can cause the body to produce antibodies to insulin (substances that act against 
• insulin). However, only very rarely, this will require a change to your insulin dose.
• Some patients with longstanding type 2 diabetes mellitus and heart disease or previous stroke who 
• were treated with pioglitazone and insulin experienced the development of heart failure. Inform your 
• doctor as soon as possible if you experience signs of heart failure such as unusual shortness of breath 
• or rapid increase in weight or localized swelling (oedema).

Ingredients:

• The active substance is insulin glargine. Each milliliter of the solution contains 100 units of the 
• active substance insulin glargine (equivalent to 3.64 mg).
• The other ingredients are: zinc oxide, metacresol, glycerol, sodium hydroxide (see section 2